These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25335860)

  • 1. Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects.
    Boyce M; Dowen S; Turnbull G; van den Berg F; Zhao CM; Chen D; Black J
    Br J Clin Pharmacol; 2015 May; 79(5):744-55. PubMed ID: 25335860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised trial of the effect of a gastrin/CCK
    Boyce M; van den Berg F; Mitchell T; Darwin K; Warrington S
    Eur J Clin Pharmacol; 2017 Feb; 73(2):129-139. PubMed ID: 27796466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Netazepide, a gastrin/CCK2 receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects.
    Boyce M; Warrington S; Black J
    Br J Clin Pharmacol; 2013 Nov; 76(5):689-98. PubMed ID: 23432534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis.
    Moore AR; Boyce M; Steele IA; Campbell F; Varro A; Pritchard DM
    PLoS One; 2013; 8(10):e76462. PubMed ID: 24098507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of repeated doses of netazepide, a gastrin receptor antagonist, omeprazole and placebo on 24 h gastric acidity and gastrin in healthy subjects.
    Boyce M; Warrington S
    Br J Clin Pharmacol; 2013 Nov; 76(5):680-8. PubMed ID: 23432415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A.
    Fossmark R; Sørdal Ø; Jianu CS; Qvigstad G; Nordrum IS; Boyce M; Waldum HL
    Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1067-75. PubMed ID: 23072686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized Controlled Trial of the Gastrin/CCK
    Abrams JA; Del Portillo A; Hills C; Compres G; Friedman RA; Cheng B; Poneros J; Lightdale CJ; De La Rue R; di Pietro M; Fitzgerald RC; Sepulveda A; Wang TC
    Cancer Prev Res (Phila); 2021 Jun; 14(6):675-682. PubMed ID: 33782049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis.
    Boyce M; Moore AR; Sagatun L; Parsons BN; Varro A; Campbell F; Fossmark R; Waldum HL; Pritchard DM
    Br J Clin Pharmacol; 2017 Mar; 83(3):466-475. PubMed ID: 27704617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CCK2 receptor antagonists: pharmacological tools to study the gastrin-ECL cell-parietal cell axis.
    Håkanson R; Ding XQ; Norlén P; Lindström E
    Regul Pept; 1999 Mar; 80(1-2):1-12. PubMed ID: 10235629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects.
    Boyce M; David O; Darwin K; Mitchell T; Johnston A; Warrington S
    Aliment Pharmacol Ther; 2012 Jul; 36(2):181-9. PubMed ID: 22607579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential clinical indications for a CCK
    Boyce M; Lloyd KA; Pritchard DM
    Curr Opin Pharmacol; 2016 Dec; 31():68-75. PubMed ID: 27710813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skeletal effects of a gastrin receptor antagonist in H+/K+ATPase beta subunit KO mice.
    Aasarød KM; Ramezanzadehkoldeh M; Shabestari M; Mosti MP; Stunes AK; Reseland JE; Beisvag V; Eriksen EF; Sandvik AK; Erben RG; Schüler C; Boyce M; Skallerud BH; Syversen U; Fossmark R
    J Endocrinol; 2016 Aug; 230(2):251-62. PubMed ID: 27325243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Netazepide Inhibits Expression of Pappalysin 2 in Type 1 Gastric Neuroendocrine Tumors.
    Lloyd KA; Parsons BN; Burkitt MD; Moore AR; Papoutsopoulou S; Boyce M; Duckworth CA; Exarchou K; Howes N; Rainbow L; Fang Y; Oxvig C; Dodd S; Varro A; Hall N; Pritchard DM
    Cell Mol Gastroenterol Hepatol; 2020; 10(1):113-132. PubMed ID: 32004755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marked increase in gastric acid secretory capacity after omeprazole treatment.
    Waldum HL; Arnestad JS; Brenna E; Eide I; Syversen U; Sandvik AK
    Gut; 1996 Nov; 39(5):649-53. PubMed ID: 9026477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cholecystokinin CCK2 receptor antagonist, JNJ-26070109, inhibits gastric acid secretion and prevents omeprazole-induced acid rebound in the rat.
    Barrett TD; Lagaud G; Wagaman P; Freedman JM; Yan W; Andries L; Rizzolio MC; Morton MF; Shankley NP
    Br J Pharmacol; 2012 Jul; 166(5):1684-93. PubMed ID: 22300007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The gastrin receptor antagonist netazepide (YF476) prevents oxyntic mucosal inflammation induced by Helicobacter pylori infection in Mongolian gerbils.
    Sørdal Ø; Waldum H; Nordrum IS; Boyce M; Bergh K; Munkvold B; Qvigstad G
    Helicobacter; 2013 Dec; 18(6):397-405. PubMed ID: 23865485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time-course of deactivation of rat stomach ECL cells following cholecystokinin B/gastrin receptor blockade.
    Ding XQ; Lindström E; Håkanson R
    Br J Pharmacol; 1997 Sep; 122(1):1-6. PubMed ID: 9298521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-lasting cholecystokinin(2) receptor blockade after a single subcutaneous injection of YF476 or YM022.
    Kitano M; Norlén P; Ding XQ; Nakamura S; Håkanson R
    Br J Pharmacol; 2000 Jun; 130(3):699-705. PubMed ID: 10821801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810).
    Lew EA; Barbuti RC; Kovacs TO; Sytnic B; Humphries TJ; Walsh JH
    Aliment Pharmacol Ther; 1998 Jul; 12(7):667-72. PubMed ID: 9701531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CCK(2) receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development.
    Kidd M; Siddique ZL; Drozdov I; Gustafsson BI; Camp RL; Black JW; Boyce M; Modlin IM
    Regul Pept; 2010 Jun; 162(1-3):52-60. PubMed ID: 20144901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.